FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Subscribe To Our Newsletter & Stay Updated
